Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Premixed Lyumjev
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
Premixed Lyumjev is a combination pharmaceutical product consisting of Lyumjev (a fast-acting insulin) and micro-doses of glucagon. It is being investigated for its potential to accelerate the absorption of insulin and enhance its effect on whole-body glucose consumption in patients with type 1 diabetes. The glucagon component is hypothesized to increase local subcutaneous blood flow at the injection site, thereby facilitating faster absorption of the co-administered insulin.
- Other names
- Glucagon/Lyumjev solutionPremixed Glucagon/Insulin Solution
02
Targets
INSR (Insulin receptor)GCGR (Glucagon receptor)
Beyond the preview
Go deeper on Premixed Lyumjev.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Premixed Lyumjev.